the absence of gut microbiota can modulate the regulation of T cell activity to contribute to the development of metastatic brain tumors. Our mechanistic studies on the role of gut microbiota in brain metastasis, peripheral and tumor immune profiling was conducted through flow cytometry subsequently injected intracranially to evaluate the effect of gut microbiota further explore the mechanistic role of the gut microbiota in brain metastasis, microbiome profiling was conducted through patients were sequenced via metagenomic shotgun and 16S rRNA OM surgical tumor resection at the University of Texas MD Anderson Cancer Center prospectively from patients with metastatic brain tumors who underwent surgical tumor resection at the University of Texas MD Anderson Cancer Center for this disease. The microbiota has emerged as a novel hallmark of cancer, with a prominent role in tumorogenesis, tumor immunity, and response to treatment. However, the role of different microbial communities in tumor metastasis, and in particular brain metastasis, is poorly understood. We hypothesize that distinct microbial communities can alter the immune microenvironment in the brain and affect brain metastasis development.

Methods: To evaluate the role of different microbial communities in brain metastasis, matched stool, saliva, tumor, and plasma samples were collected prospectively from patients with metastatic brain tumors who underwent surgical tumor resection at the University of Texas MD Anderson Cancer Center. Stool and saliva samples were collected using the 16S rRNA microbiome collection and stabilization kits (DNAgenoek, Kit # OM-200 and OM-505, respectively). Tumor samples were flash frozen in sterile conditions. Stool and saliva samples from 30 patients and tumor and plasma from 15 patients were sequenced via metagenomic shotgun and 16S rRNA sequencing, respectively. Microbiome profiling was conducted through established computational pipelines reported previously by our group. To further explore the mechanistic role of the gut microbiota in brain metastasis, we depleted gut microbiota in conventionally raised mice using a broad-spectrum non-absorbable antibiotic regimen. Melanoma tumor cells were subsequently injected intracranially to evaluate the effect of gut microbiota depletion and associated immune changes on tumor growth. Tumor growth was measured through in vivo bioluminescent imaging and histology. Peripheral and tumor immune profiling was conducted through flow cytometry and immunohistochemistry.

Results: In all types of microbiota evaluated in this study, distinct signatures were identified to be associated with brain metastasis compared to other types of brain tumors. Interestingly, we demonstrated an overlap between the tumor microbiome and the oral microbiome but not with the gut microbiome. These findings suggest a direct contribution of the oral microbiome and the potential indirect contribution of the gut microbiome to the development of brain metastasis. Our mechanistic studies on the role of gut microbiota in brain metastasis demonstrated that depletion of the gut microbiota in mice decreased tumor growth in the brain. Evaluation of the peripheral and tumor immune profiles suggested the underlying mechanisms to involve alterations in the circulating cytokine profiles and an increase in anti-tumor T cell activity.

Conclusions: Our clinical studies suggest the association of distinct microbial communities with brain metastasis. Our pre-clinical findings demonstrate that the absence of gut microbiota can modulate the regulation of T cell activity to induce an anti-tumor response in the brain. Further studies, currently in progress, will determine the individual and collective role of different microbial communities in the development of brain metastasis.

Background: Metastatic brain tumors are associated with significant morbidity and mortality. The current limited understanding of the mechanisms underlying brain metastasis has hindered the development of efficient diagnostics and therapeutics for this disease. The microbiota has emerged as a novel hallmark of cancer, with a prominent role in tumorogenesis, tumor immunity, and response to treatment. However, the role of different microbial communities in tumor metastasis, and in particular brain metastasis, is poorly understood. We hypothesize that distinct microbial communities can alter the immune microenvironment in the brain and affect brain metastasis development.

Methods: To evaluate the role of different microbial communities in brain metastasis, matched stool, saliva, tumor, and plasma samples were collected prospectively from patients with metastatic brain tumors who underwent surgical tumor resection at the University of Texas MD Anderson Cancer Center. Stool and saliva samples were collected using the OMNigene microbiome collection and stabilization kits (DNAgenoek, Kit # OM-200 and OM-505, respectively). Tumor samples were flash frozen in sterile conditions. Stool and saliva samples from 30 patients and tumor and plasma from 15 patients were sequenced via metagenomic shotgun and 16S rRNA sequencing, respectively. Microbiome profiling was conducted through established computational pipelines reported previously by our group. To further explore the mechanistic role of the gut microbiota in brain metastasis, we depleted gut microbiota in conventionally raised mice using a broad-spectrum non-absorbable antibiotic regimen. Melanoma tumor cells were subsequently injected intracranially to evaluate the effect of gut microbiota depletion and associated immune changes on tumor growth. Tumor growth was measured through in vivo bioluminescent imaging and histology. Peripheral and tumor immune profiling was conducted through flow cytometry and immunohistochemistry.

Results: In all types of microbiota evaluated in this study, distinct signatures were identified to be associated with brain metastasis compared to other types of brain tumors. Interestingly, we demonstrated an overlap between the tumor microbiome and the oral microbiome but not with the gut microbiome. These findings suggest a direct contribution of the oral microbiome and the potential indirect contribution of the gut microbiome to the development of brain metastasis. Our mechanistic studies on the role of gut microbiota in brain metastasis demonstrated that depletion of the gut microbiota in mice decreased tumor growth in the brain. Evaluation of the peripheral and tumor immune profiles suggested the underlying mechanisms to involve alterations in the circulating cytokine profiles and an increase in anti-tumor T cell activity.

Conclusions: Our clinical studies suggest the association of distinct microbial communities with brain metastasis. Our pre-clinical findings demonstrate that the absence of gut microbiota can modulate the regulation of T cell activity to induce an anti-tumor response in the brain. We identified distinct gut, oral, and tumor bacterial signatures that were enriched in brain metastasis patients compared to primary tumors. Our findings suggest a direct contribution of the oral microbiome and the potential indirect contribution of the gut microbiome to the development of brain metastasis. Our pre-clinical findings demonstrate that the absence of gut microbiota can modulate the regulation of T cell activity to induce an anti-tumor response in the brain.

References:
1. Gopalakrishnan et al., Science 2018
2. Helsmink et al., Nature Medicine 2019
3. Morais et al., Nature Reviews Microbiology 2021

Acknowledgements:
National Institute of Health F32CA260769